When Genetics Meets Vaccines: New Clues Behind Clotting Reactions

A major new study has shed light on one of the most puzzling vaccine-related complications identified during the COVID-19 pandemic: vaccine-induced immune thrombotic thrombocytopenia (VITT). This rare condition, linked primarily to adenovirus-based COVID-19 vaccines such as Johnson & Johnson and AstraZeneca, involves unusual blood clotting combined with low platelet counts.

For years, scientists have debated what triggered VITT and why it appeared in only a tiny fraction of people. New research now provides the clearest explanation yet — and suggests that both immune biology and genetics play a role.

When VITT cases first emerged in 2021, researchers noticed that affected patients developed antibodies against platelet factor 4 (PF4), a molecule involved in blood clotting. What remained unclear was why the immune system would suddenly target PF4 after vaccination.

The new study points strongly to the adenovirus vector itself as the initial trigger. Researchers found that in people who developed VITT, certain antibodies first recognized a protein from the adenovirus used in the vaccine. Due to a specific change in those antibodies, they also began reacting to PF4 — leading to clotting.

In other words, the immune system wasn’t originally attacking the body. It was reacting to the vaccine’s viral component, and then, through a biological misfire, began targeting a human protein involved in coagulation.



One of the most significant findings is that this immune response appears tied to specific genetic variants.

Researchers identified particular immunoglobulin gene types shared among patients with VITT. However, genetics alone did not cause the condition. The antibodies also showed an additional small mutation — called a somatic hypermutation — that changed how they recognized targets.

This “two-step” process means that if a person carries certain genetic variants and a specific mutation occurs in immune cells after exposure, the resulting antibodies cross-react with PF4 and trigger clotting.

Together, these findings offer the first detailed biological model of how VITT develops.

The discovery naturally raises a question: if certain DNA variants increase susceptibility, could genetic screening help people make more informed choices about vaccination?

That idea is scientifically plausible but still premature. Key considerations remain:

  • The identified variants are not extremely rare and do not predict VITT on their own.

  • The dangerous immune mutation is unpredictable and occurs only in exceptional cases.

  • COVID-19 infection itself is linked to clotting and other serious complications.

Future research may determine whether screening could meaningfully reduce risk, especially for specific vaccine platforms. For now, experts view the findings as a step toward safer vaccine design rather than a tool for routine pre-vaccination testing.

During the pandemic, many people reported strokes, sudden illness, fainting episodes, and other events after vaccination. Some cases were investigated and linked to VITT or other rare complications; many others were not causally connected.

Scientists now believe adenovirus-based vaccines could be redesigned to avoid the protein region that triggered the problematic immune response. Rather than abandoning the platform entirely, researchers may be able to engineer around the issue.

That’s significant because adenovirus vaccines remain valuable tools — especially in global health settings where they are easier to produce, store, and distribute.

As science continues to map the intersection of genetics, immunity, and vaccination, the future likely includes vaccines that are not only effective, but increasingly personalized and safer for everyone.


REFERENCE

Wang JJ, Schönborn L, Warkentin TE, Müller L, Thiele T, Ulm L, Völker U, Ameling S, Franzenburg S, Kaderali L, Tzvetkova A, Colella A, Chataway T, Tan CW, Armour B, Troelnikov A, Rutten L, McCluskey J, Zahn R, Gordon TP, Greinacher A. Adenoviral Inciting Antigen and Somatic Hypermutation in VITT. N Engl J Med. 2026 Feb 12;394(7):669-683. doi: 10.1056/NEJMoa2514824. PMID: 41671482.



Comments

Post a Comment

Popular posts from this blog

Severe autoimmune ganglionopathy after COVID19 vaccination

Image
A previously hypertensive 56-year-old male presented with the subacute onset of severe constipation, urinary retention, erectile dysfunction, sudomotor failure, sicca symptoms, non-reactive pupils and severe orthostatic hypotension shortly after receiving the second dose of the Comirnaty mRNA vaccine against COVID19.  Autonomic testing revealed severe cardiovagal, adrenergic and sudomotor impairment, and tonic 'half-mast' pupils with evidence of sympathetic and parasympathetic denervation (see Figure). T ilt-table testing demonstrated a drop in blood pressure from 140/90 mmHg supine to 54/35 mmHg after two minutes at 60 degrees, with no heart rate response.  There was no heart rate response to Valsalva maneuver  and sympathetic skin responses in the hands and feet were absent. Sweat testing demonstrated complete anhidrosis. Pathological α3-ganglionic ACHR antibodies were positive in serum as detected by a new flow cytometric immunomodulation assay. Malignancy wa...
Read more

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis ...
Read more

Toothache as a side effect of vaccination

Image
Previously we presented case reports with oral side effects of COVID-19 vaccine due to mucocutaneous reactions. Trigeminal neuralgia (TN) could be another reason for oral manifestations, including severe tooth pain.  A 45-year-old female was admitted to a research hospital with 3 days of facial and jaw pain, fatigue and toothache following the first dose of Pfizer-BioNtech vaccine against SARS-CoV-2. The features of the pain were unilateral, acute onset, and severe, on the lower right side of the face. It was triggering with brushing her teeth and putting on makeup. The case was considered as trigeminal neuralgia. Pregabalin failed to control the pain, while amoxicillin/clavulanic acid (despite normal X-rays) led to angioedema and worsening of her general condition. However, with steroid treatment, the patient eventually recovered.  A 36-year-old woman was admitted to the Emergency Ward due to chronic pain attacks in the left side of her face. The pain appeared tw...
Read more